Login to Your Account

Astex Strikes $500M Deal for its Fibroblast Receptor

By Nuala Moran

Tuesday, June 10, 2008
LONDON - Astex Therapeutics Ltd. sealed a deal worth a potential $500 million, licensing its fibroblast growth factor receptor (FGFR) inhibitor and agreeing on a drug discovery program around two cancer targets, with Janssen Pharmaceutica NV. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription